Uroselective Alpha-1-Antagonist to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery

NCT07174349 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Urinary Retention Postoperative

Interventions

DRUG: Uroselective alpha-1-adrenergic receptor antagonist
OTHER: Placebo

Sponsor

Mayo Clinic